Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

PLoS One · 2014 · PMC4171508 · PMID 25244440

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0930

boldest claim

The sentences

borderline significantp = 0.06so close (0.05 < p ≤ 0.1)

Although only borderline significant, in contrast to CD34+CD38-, the neoplastic CD34+CD38+ compartment was even smaller in non-CR patients than in CR patients (10.8% of WBC versus 23.7% of WBC; p = 0.06).

also in 11,409 other papers

showed a trendp = 0.093so close (0.05 < p ≤ 0.1)

Other factors showed a trend: NPM1 mutation (p = 0.093, n = 140) and EVI-1 (p = 0.18, n = 140). n.r. not relevant since all evaluated patients achieved CR after first cycle RR, relative risk of relapse. * only the most optimal cut-offs (0.0003% after 1 st cycle and 0.0001% after 2 nd and consolidation cycle) are shown.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.